Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present AzurRx BioPharma, Inc. (NASDAQ: AZRX).

Full DD Report for AZRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: AZRX)

AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study of MS1819-SD in CF Patients with EPI
On track to initiate Phase 2 trial in cystic fibrosis patients in the fourth quarter of 2018 and conclude in 2019   NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in t...
Source: GlobeNewswire
Date: November, 01 2018 07:30
AzurRx BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference on September 5th
BROOKLYN, N.Y., Aug. 28, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company wil...
Source: GlobeNewswire
Date: August, 28 2018 08:30
AzurRx BioPharma to Present at the 2018 Cannacord Genuity 38th Annual Growth Conference (August 9th)
BROOKLYN, N.Y., Aug. 01, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company will be...
Source: GlobeNewswire
Date: August, 01 2018 08:30
Your Daily Pharma Scoop: Spectrum Trial Proceeds, AzurRx Moves To Phase 3, Aptose Jumps
Stocks in News: SPPI, AZRX Spectrum reports second late-stage Rolontis trial meets primary endpoint Discussion : Second Phase 3 trial of Spectrum Pharmaceutical’s ( SPPI ) Rolontis met primary efficacy endpoint. The endpoint was non-inferiority in duration of severe neutropenia...
Source: SeekingAlpha
Date: July, 02 2018 07:20
AzurRx Biopharma announces successful Phase IIa trial of MS1819-SD in exocrine pancreatic insufficiency
AzurRx BioPharma (NASDAQ: AZRX ) in partnership with Mayoly Spindler announced the completion of its Phase IIa trial of MS1819-SD, a recombinant lipase, for the treatment of exocrine pancreatic insufficiency ("EPI") caused by chronic pancreatitis. More news on: AzurRX Biopharma, Healthcare...
Source: SeekingAlpha
Date: June, 29 2018 08:47
AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency
NEW YORK, June 29, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced, in partnership...
Source: GlobeNewswire
Date: June, 29 2018 08:30
Midday Gainers / Losers (06/08/2018)
Gainers: TPIV +71% . EDAP +63% . SVRA +30% . ACOR +19% . SFIX +15% . TTOO +13% . NFEC +13% . AZRX +13% . VSI +12% . ZYME +13% . More news on: TapImmune, Inc., EDAP TMS S.A., Savara Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: June, 08 2018 12:40
AzurRx Announces Appointment of Dr. James Pennington as Chief Medical Officer
NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced the appointment ...
Source: GlobeNewswire
Date: May, 30 2018 08:03
Premarket Losers as of 9:05 am (5/1/2018)
IVAC   -24%  on Q1 earnings . More news on: Intevac, Inc., CommScope Holding Company Inc., Cognex Corporation, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 01 2018 09:13
AzurRx BioPharma Announces Pricing of $10.4 Million Public Offering of Common Stock
BROOKLYN, N.Y., May 01, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma (NASDAQ:AZRX), (“AzurRx” or the “Company”), today announced the pricing of an underwritten public offering of 4,160,000 shares of its common stock at an offering price of $2.50 per share. The gross...
Source: GlobeNewswire
Date: May, 01 2018 09:10

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-092.562.652.652.5611,035
2018-05-182.54152.462.54152.401616,082
2018-05-172.54152.462.54152.401616,082
2017-02-034.494.4554.504.432,565
2017-02-024.48994.43994.48994.43164,097

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-077,0008,10086.4198Short
2018-12-064,87470,4746.9160Cover
2018-12-042,1006,44532.5834Cover
2018-12-032511,8890.2103Cover
2018-11-306,60765,64010.0655Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AZRX.


About AzurRx BioPharma, Inc. (NASDAQ: AZRX)

Logo for AzurRx BioPharma, Inc. (NASDAQ: AZRX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: AZRX)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 14 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: May, 11 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: May, 11 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: May, 11 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: May, 11 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 04 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 04 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: May, 02 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: May, 02 2018
      Registration of up to an additional 20% of securities for any offering registered on a S-3
      Filing Type: S-3MEFFiling Source: edgar
      Filing Date: May, 01 2018

       

       


      Daily Technical Chart for (NASDAQ: AZRX)

      Daily Technical Chart for (NASDAQ: AZRX)


      Stay tuned for daily updates and more on (NASDAQ: AZRX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: AZRX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AZRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AZRX and does not buy, sell, or trade any shares of AZRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/